Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Common Equity (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed Common Equity for 3 consecutive years, with $47.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 24.45% to $47.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.7 million through Dec 2025, down 24.45% year-over-year, with the annual reading at $47.7 million for FY2025, 24.45% down from the prior year.
  • Common Equity hit $47.7 million in Q4 2025 for Camp4 Therapeutics, down from $58.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $63.1 million in Q4 2024 to a low of -$159.0 million in Q3 2024.
  • Historically, Common Equity has averaged -$41.6 million across 3 years, with a median of -$35.8 million in 2023.
  • Biggest YoY gain for Common Equity was 151.03% in 2024; the steepest drop was 42.51% in 2024.
  • Year by year, Common Equity stood at -$123.7 million in 2023, then surged by 151.03% to $63.1 million in 2024, then fell by 24.45% to $47.7 million in 2025.
  • Business Quant data shows Common Equity for CAMP at $47.7 million in Q4 2025, $58.7 million in Q3 2025, and $40.0 million in Q2 2025.